Fluxion, Rubicon Team on CTC Applications | GenomeWeb

NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

The South San Francisco, Calif.-based firm said that the alliance will integrate enrichment methods for rare cells using Fluxion's IsoFlux System with Rubicon's NovaPlex sample preparation kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.